Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.51 |
| ▸ | CCR2 | P41597 | 9/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148943 | 1.00 | PTGDR (0.51) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3049324 | 0.94 | CCR2 (0.46) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3050733 | 0.94 | CCR2 (0.46) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3143241 | 0.93 | PTGDR (0.55) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3143246 | 0.93 | PTGDR (0.55) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3149310 | 0.90 | CCR2 (0.49) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3149304 | 0.90 | CCR2 (0.49) | PTGDRPTGDR2CCR2DRD3HTR2A | |
| SCHEMBL3143685 | 0.87 | CCR2 (0.56) | PTGDRPTGDR2CCR2DRD3DRD2 | |
| SCHEMBL3143680 | 0.87 | CCR2 (0.56) | PTGDRPTGDR2CCR2DRD3DRD2 | |
| SCHEMBL15103930 | 0.87 | CCR2 (0.47) | PTGDRPTGDR2CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | PTGDR 48/4885PTGDR2 83/4885CCR2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.